Annual Report 2015-16
Annual Report 2011-12
Corporate Presentation
Q1 FY14
Corporate Brochure
Apply Online
About Us
Philosophy
Vision & Mission
Values
Management & Board
MD's Message
MD's Page
Board of Directors
Management Team
History & Milestones
Corporate Governance
Safety Excellence
Quality
Environment Sustainability
CSR Endeavours
Orchid Trust
Focus Areas
Awards & Accolades
Products
Formulations (Domestic)
Cardiovascular
Anti-Diabetic
Neuropsychiatry
Nutritional Supplements
Others
API
Cephalosporins - Orals
Cephalosporins - Injectibles
Veterinary Products
Non-Antibiotics
R&D
Infrastructure
Capabilities
Process & Pharma Research
New Drug Discovery
Pre-clinical Research
Novel Drug Delivery Systems
Biotech Research
Intellectual Property Management
CRAMS
Infrastructure
Formulations
API
Investors
Chairman's Speech
Board of Directors
Committee Composition
Appointment Letters
Fact Sheet
Financials
Shareholding
Downloads
Analyst Coverage
Intimation to SE's
Investor Grievance Redressal
Unclaimed Dividend
Orchid Stock Info
Listing Of Securities
High/Lows
Historical Share Price
Share Price Movement
10 Years Trend
IEPF Share Transfer
Media Press releases
Media
Press Releases
Photo Gallery
Video Gallery
Subscribe Alerts
Downloads
Media Kit
Careers
Spirit of Orchid!
Our Secret Ingredients
Why become an Orchidian?
Apply Online
Worldwide Operations
Partner With Us
Partnering for Success
Want to partner with us?
Contact
Global Headquarters
API
Formulations
R&D
Home
»
Media
»
Press Releases
Media
Press Releases
Photo Gallery
Video Gallery
Subscribe Alerts
Downloads
Media Kit
Press Releases
back
Orchid Pharma registers turnover of Rs 204 crore in Q3 FY16, EBITDA of Rs 39 crore.
Chennai, India | February 10, 2016
Orchid Pharma registers turnover of Rs 204 crore in Q3 FY16, EBITDA of Rs 39 crore.
replica watches